Form 13-F position report

LYRA THERAPEUTICS INC

Reported by MORGAN STANLEY

LYRA CUSIP 55234L105 Manager CIK 0000895421

First reported at 510 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 510 Quarter-end amount reported
Reported value $2,096 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 41000
2022-03-31 33000
2022-06-30 0
2022-12-31 3
2023-03-31 0
2023-06-30 2096
2023-09-30 0
2024-03-31 400519
2024-06-30 224610
2024-09-30 167663
2024-12-31 44682
2025-03-31 8287
2025-06-30 0
2025-06-30 19389
2025-09-30 8335
2025-12-31 1029
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for LYRA THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -334 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 334 -943 (-73.8%) < 0.01% $1,029 2026-02-13
Q3 2025 Reduced 1,277 -887 (-41.0%) < 0.01% $8,335 2025-11-14
Q2 2025 New 2,164 +2,164 (0.0%) < 0.01% $19,389 2025-08-15
Q2 2025 Reduced 0 -65,619 (-100.0%) 0 $0 2025-08-15
Q1 2025 Reduced 65,619 -150,866 (-69.7%) < 0.01% $8,287 2025-05-15
Q4 2024 Reduced 216,485 -435,896 (-66.8%) < 0.01% $44,682 2025-02-14
Q3 2024 Reduced 652,381 -159,364 (-19.6%) < 0.01% $167,663 2024-11-14
Q2 2024 Added 811,745 +747,353 (1160.6%) < 0.01% $224,610 2024-08-14
Q1 2024 New 64,392 +64,392 (0.0%) < 0.01% $400,519 2024-05-15
Q3 2023 Reduced 0 -510 (-100.0%) 0 $0 2023-11-15
Q2 2023 New 510 +510 (0.0%) < 0.01% $2,096 2023-08-14
Q1 2023 Reduced 0 -1 (-100.0%) 0 $0 2023-05-15
Q4 2022 New 1 +1 (0.0%) < 0.01% $3 2023-02-14
Q2 2022 Reduced 0 -8,085 (-100.0%) 0 $0 2022-08-15
Q1 2022 Reduced 8,085 -1,346 (-14.3%) < 0.01% $33,000 2022-05-13
Q4 2021 Reduced 9,431 -20,732 (-68.7%) < 0.01% $41,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

44 managers reported LYRA THERAPEUTICS INC for Q2 2023.

Managers reporting LYRA THERAPEUTICS INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PERCEPTIVE ADVISORS LLC Added 12,757,562 +3,610,832 1.52% $52,433,579 13 qtrs
ARMISTICE CAPITAL LLC New 4,012,036 +4,012,036 0.24% $16,489,468 1 qtr
Nantahala Capital Management LLC Added 3,957,542 +1,736,712 1.57% $16,265,497 5 qtrs
CITADEL ADVISORS LLC Added 2,849,178 +2,841,244 < 0.01% $11,710,122 4 qtrs
Samsara BioCapital LLC Added 2,780,261 +1,003,010 2.01% $11,426,873 5 qtrs
PURA VIDA INVESTMENTS LLC Reduced 1,413,242 -583,730 0.76% $5,717,732 9 qtrs
Ikarian Capital LLC Added 978,626 +634,941 0.64% $4,022,153 12 qtrs
VR Adviser LLC Unchanged 924,170 0 0.61% $3,798,339 5 qtrs
VANGUARD GROUP INC Unchanged 790,936 0 < 0.01% $3,250,747 13 qtrs
Parkman Healthcare Partners LLC New 600,000 +600,000 0.43% $2,466,000 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
510
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.